Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Glaucoma: Overview01:25

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
Nephrotic Syndrome I : Introduction01:24

Nephrotic Syndrome I : Introduction

Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of fluid...
Diabetic Nephropathy01:28

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Recurrent focal segmental glomerulosclerosis in the renal allograft: single center experience in the era of modern immunosuppression.

Clinical nephrology·2010
Same author

Sensitivity, specificity and clinical relevance of different cross-matching assays in deceased-donor renal transplantation.

Transplant immunology·2008
Same author

Supersized kidneys: Lessons from the preclinical obese kidney.

Kidney international·2008
Same author

Myeloma cast nephropathy, direct renal infiltration by myeloma, and renal extramedullary hematopoiesis.

Kidney international·2008
Same author

Uromodulin storage disease.

Kidney international·2007
Same author

Uveitis and acute renal failure.

Kidney international·2007
Same journal

Crystal-Storing Histiocytosis Causing Severe AKI.

Kidney international·2026
Same journal

Peritoneal dialysis in a patient with extensive burn scarring.

Kidney international·2026
Same journal

COPA syndrome unmasked by anti-neutrophil cytoplasmic antibody-positive immune-complex nephritis.

Kidney international·2026
Same journal

Monitoring anti-nephrin antibodies in the management of recurrent diffuse podocytopathy.

Kidney international·2026
Same journal

The "Hear My Last Wish" Initiative: Leveraging Voiceprint Technology to Bridge the Gap Between Donor Intent and Family Consent in Taiwan.

Kidney international·2026
Same journal

A three-year randomized, double-blind, placebo-controlled study of lanreotide in stage 2/3 autosomal dominant polycystic kidney disease.

Kidney international·2026
See all related articles

Related Experiment Video

Updated: Jun 20, 2026

An Advanced Murine Model for Nonalcoholic Steatohepatitis in Association with Type 2 Diabetes
10:17

An Advanced Murine Model for Nonalcoholic Steatohepatitis in Association with Type 2 Diabetes

Published on: April 26, 2019

Obesity-related glomerulopathy: an emerging epidemic.

N Kambham1, G S Markowitz, A M Valeri

  • 1Department of Pathology, Columbia University, College of Physicians and Surgeons, New York, New York 10032, USA.

Kidney International
|March 22, 2001
PubMed
Summary
This summary is machine-generated.

Obesity-related glomerulopathy (ORG) shows a ten-fold increase in incidence, distinct from idiopathic FSGS with milder features and a better prognosis. Increased physician awareness is crucial for accurate diagnosis and treatment.

More Related Videos

An Assay to Detect Protection of the Retinal Vasculature from Diabetes-Related Death in Mice
04:36

An Assay to Detect Protection of the Retinal Vasculature from Diabetes-Related Death in Mice

Published on: January 12, 2024

Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

Related Experiment Videos

Last Updated: Jun 20, 2026

An Advanced Murine Model for Nonalcoholic Steatohepatitis in Association with Type 2 Diabetes
10:17

An Advanced Murine Model for Nonalcoholic Steatohepatitis in Association with Type 2 Diabetes

Published on: April 26, 2019

An Assay to Detect Protection of the Retinal Vasculature from Diabetes-Related Death in Mice
04:36

An Assay to Detect Protection of the Retinal Vasculature from Diabetes-Related Death in Mice

Published on: January 12, 2024

Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

Area of Science:

  • Nephrology
  • Pathology
  • Epidemiology

Background:

  • Obesity-related glomerulopathy (ORG) is a growing concern, necessitating clinicopathologic study.
  • This study presents the first large renal biopsy-based analysis of ORG.

Purpose of the Study:

  • To investigate the clinicopathologic features and incidence trends of ORG.
  • To compare ORG with idiopathic focal segmental glomerulosclerosis (I-FSGS).

Main Methods:

  • Analysis of 6818 native renal biopsies from 1986-2000.
  • Morphological definition of ORG: focal segmental glomerulosclerosis and glomerulomegaly (O-FSGS) or glomerulomegaly alone (O-GM).
  • Comparison of ORG patients (N=71) with I-FSGS patients (N=50).

Main Results:

  • ORG incidence increased tenfold from 0.2% to 2.0% between 1986-2000.
  • ORG patients exhibited higher BMI, were older, and more often Caucasian than I-FSGS patients.
  • ORG showed lower nephrotic range proteinuria, less edema, milder foot process effacement, and significantly larger glomerular size compared to I-FSGS.
  • ORG patients had a significantly lower risk of doubling serum creatinine and progression to end-stage renal disease (ESRD).

Conclusions:

  • ORG is a distinct entity from I-FSGS, characterized by glomerulomegaly and a more indolent clinical course.
  • The rising incidence of ORG suggests an emerging epidemic requiring greater physician awareness.
  • Accurate diagnosis and appropriate management, potentially including ACE inhibition or A2 blockade, are vital for ORG patients.